125 related articles for article (PubMed ID: 34461087)
61. Tools for the rational design of bivalent microtubule-targeting drugs.
Marangon J; Christodoulou MS; Casagrande FV; Tiana G; Dalla Via L; Aliverti A; Passarella D; Cappelletti G; Ricagno S
Biochem Biophys Res Commun; 2016 Oct; 479(1):48-53. PubMed ID: 27613098
[TBL] [Abstract][Full Text] [Related]
62. Molecular interaction of cryptophycin 52 with Caspase 8 for the management of lung cancer during coronavirus outbreak : A computational study.
Leena Hussein Bajrai ; Sayed Sartaj Sohrab ; Mohammad Khalid ; Mohammad A Kamal ; Esam Ibraheem Azhar
Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):31-35. PubMed ID: 36227681
[TBL] [Abstract][Full Text] [Related]
63. Cryptophycin affinity labels: synthesis and biological activity of a benzophenone analogue of cryptophycin-24.
Vidya R; Eggen M; Georg GI; Himes RH
Bioorg Med Chem Lett; 2003 Feb; 13(4):757-60. PubMed ID: 12639575
[TBL] [Abstract][Full Text] [Related]
64. Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jan; 47(3):696-702. PubMed ID: 14736249
[TBL] [Abstract][Full Text] [Related]
65. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
Edelman MJ; Gandara DR; Hausner P; Israel V; Thornton D; DeSanto J; Doyle LA
Lung Cancer; 2003 Feb; 39(2):197-9. PubMed ID: 12581573
[TBL] [Abstract][Full Text] [Related]
66. Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates.
Anselmi M; Borbély A; Figueras E; Michalek C; Kemker I; Gentilucci L; Sewald N
Chemistry; 2021 Jan; 27(3):1015-1022. PubMed ID: 32955139
[TBL] [Abstract][Full Text] [Related]
67. Recent approaches for the synthesis of modified cryptophycins.
Weiss C; Sammet B; Sewald N
Nat Prod Rep; 2013 Jul; 30(7):924-40. PubMed ID: 23732943
[TBL] [Abstract][Full Text] [Related]
68. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
69. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
[TBL] [Abstract][Full Text] [Related]
70. Structural Basis of Microtubule Stabilization by Discodermolide.
Prota AE; Bargsten K; Redondo-Horcajo M; Smith AB; Yang CH; McDaid HM; Paterson I; Horwitz SB; Fernando Díaz J; Steinmetz MO
Chembiochem; 2017 May; 18(10):905-909. PubMed ID: 28207984
[TBL] [Abstract][Full Text] [Related]
71. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
[TBL] [Abstract][Full Text] [Related]
72. NMK-TD-100, a novel microtubule modulating agent, blocks mitosis and induces apoptosis in HeLa cells by binding to tubulin.
Bhattacharya S; Kumar NM; Ganguli A; Tantak MP; Kumar D; Chakrabarti G
PLoS One; 2013; 8(10):e76286. PubMed ID: 24116100
[TBL] [Abstract][Full Text] [Related]
73. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
[TBL] [Abstract][Full Text] [Related]
74. Biosynthetic characterization and chemoenzymatic assembly of the cryptophycins. Potent anticancer agents from cyanobionts.
Magarvey NA; Beck ZQ; Golakoti T; Ding Y; Huber U; Hemscheidt TK; Abelson D; Moore RE; Sherman DH
ACS Chem Biol; 2006 Dec; 1(12):766-79. PubMed ID: 17240975
[TBL] [Abstract][Full Text] [Related]
75. Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine.
Mohan L; Raghav D; Ashraf SM; Sebastian J; Rathinasamy K
Biomed Pharmacother; 2018 Sep; 105():506-517. PubMed ID: 29883946
[TBL] [Abstract][Full Text] [Related]
76. Diverse balances of tubulin interactions and shape change drive and interrupt microtubule depolymerization.
Bollinger JA; Stevens MJ
Soft Matter; 2019 Oct; 15(40):8137-8146. PubMed ID: 31593193
[TBL] [Abstract][Full Text] [Related]
77. A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin.
Sawada T; Kato Y; Kobayashi H; Hashimoto Y; Watanabe T; Sugiyama Y; Iwasaki S
Bioconjug Chem; 1993; 4(4):284-9. PubMed ID: 8218485
[TBL] [Abstract][Full Text] [Related]
78. Synthesis and biological activities of hapalosin derivatives with modification at the C12 position.
Kashihara N; To-e S; Nakamura K; Umezawa K; Yamamura S; Nishiyama S
Bioorg Med Chem Lett; 2000 Jan; 10(2):101-3. PubMed ID: 10673089
[TBL] [Abstract][Full Text] [Related]
79. Synthesis of cryptophycin 52 using the Shi epoxidation.
Hoard DW; Moher ED; Martinelli MJ; Norman BH
Org Lett; 2002 May; 4(10):1813-5. PubMed ID: 12000306
[TBL] [Abstract][Full Text] [Related]
80. Estradiol dimer inhibits tubulin polymerization and microtubule dynamics.
Jurášek M; Černohorská M; Řehulka J; Spiwok V; Sulimenko T; Dráberová E; Darmostuk M; Gurská S; Frydrych I; Buriánová R; Ruml T; Hajdúch M; Bartůněk P; Dráber P; Džubák P; Drašar PB; Sedlák D
J Steroid Biochem Mol Biol; 2018 Oct; 183():68-79. PubMed ID: 29803726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
